Jiangzhong Pharmaceutical: Jiangzhong Pharmaceutical Co., Ltd. is a family-owned pharmaceutical company in Jiangxi Province. The company mainly deals with proprietary Chinese medicines, traditional Chinese medicine preparations, antibiotic raw materials, antibiotic preparations, etc. The company mainly produces OTC drugs, and its leading products are Jiangzhong compound grass coral buccal tablets, Jiangzhong Jianwei Xiaoshi tablets, Jiangzhong Liangsheng tablets, etc., which have strong market competitiveness. Jiangzhong Liangsheng is even more honored as "the favorite brand of consumers in China pharmaceutical market".

Zhejiang Medicine: Zhejiang Pharmaceutical Co., Ltd. is a company mainly engaged in pharmaceutical production and sales, and its main products include tablets, capsules, oral liquids, injections, APIs, etc. It is an important manufacturer of APIs and preparations in China. It has become an important production base of vitamins, antibiotic resistant bacteria and quinolone products in China. The annual output of the company's leading product, vitamin E, ranks first in China and third in the world. In the Lailixin series, the company is one of the "top three" of levofloxacin in China. The company's new coenzyme additive FED ranks third in the world, and it is the only enterprise in China that uses fermentation. In addition, the company is the only manufacturer that produces benzofluorenol in China at present. The monopoly position of the industry is very prominent. Xinchang Pharmaceutical Factory, a subsidiary of the company, has been listed as a national biotin production base by China Feed Engineering Technology Research Center, and the production and sales volume of vitamin H and kitasamycin ranks third in the world.

tonghua dongbao: tonghua dongbao Pharmaceutical Co., Ltd. is mainly engaged in Chinese and western medicines, biological products and plastic building materials, and it is a key high-tech enterprise in the Torch Program recognized by the Ministry of Science and Technology. The company's trademark "Dongbao" has been recognized as a well-known trademark in China by the State Administration for Industry and Commerce. The company has a series of products represented by recombinant human insulin (trade name: Ganshulin), and its product "Ganshulin" fills the gap in China, making China a country that can produce recombinant human insulin and glargine after the United States and Denmark. In 22, the scientific research achievements of recombinant human insulin won the second prize of National Science and Technology Progress Award. In 21, the industrialization of recombinant human insulin project declared by the company won the first prize of Jilin Federation of Industry and Commerce and the first prize of Tonghua City. Recombinant human insulin injection Ganshulin 3R obtained famous brand products in Jilin Province.